X-ZELL Next-Generation Cytology (NGC) platform now IVDR-compliant and FDA-listed
Medical technology company achieves direct market access
SINGAPORE, March 21, 2024 /EINPresswire.com/ — X-ZELL is proud to announce that the company’s ground-breaking Next-Generation Cytology (NGC) technology is now officially available for routine use in Europe and the US. X-ZELL NGC is a platform technology combining next-generation immunostaining with digital imaging to facilitate same-day cancer diagnoses from minimally invasive samples in routine laboratories worldwide.
